Skip to main content

Toujeo SoloStar FDA Approval History

FDA Approved: Yes (First approved February 25, 2015)
Brand name: Toujeo SoloStar
Generic name: insulin glargine [rDNA origin]
Dosage form: Injection
Previous Name: Toujeo
Company: Sanofi
Treatment for: Diabetes, Type 1, Diabetes, Type 2

Toujeo SoloStar (insulin glargine [rDNA origin] is a once-daily long-acting basal insulin used to improve glycemic control in adults with type 1 and type 2 diabetes.

Development timeline for Toujeo SoloStar

Mar 27, 2018Approval FDA Approves Toujeo (insulin glargine) Max SoloStar
Feb 25, 2015Approval Sanofi Receives FDA Approval of Once-Daily Basal Insulin Toujeo
Jul  8, 2014FDA Accepts Sanofi's New Drug Application for Basal Insulin Toujeo

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.